Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL8332170 | 0.84 | TAAR1 (0.54) | TSHRALDH1A1AOC3TAAR1KMT2A | |
| Ethylbenzene SCHEMBL27308197 | 0.83 | TP53 (0.82) | TP53TSHRALDH1A1AOC3TAAR1 | |
| Ethylbenzene SCHEMBL27491778 | 0.81 | TP53 (0.70) | TP53TSHRALDH1A1TAAR1MEN1 | |
| Ethylbenzene SCHEMBL27348345 | 0.81 | TP53 (0.70) | TP53ALDH1A1TAAR1MEN1KMT2A | |
| Ethylbenzene SCHEMBL28002777 | 0.81 | TP53 (0.70) | TP53ALDH1A1TAAR1MEN1KMT2A | |
| Ethylbenzene SCHEMBL27816632 | 0.80 | TP53 (0.78) | TP53TSHRALDH1A1AOC3TAAR1 | |
| (Chloromethyl)Benzene SCHEMBL11863187 | 0.80 | ALDH1A1 (0.43) | TP53TSHRALDH1A1AOC3TAAR1 | |
| Benzyl Bromide SCHEMBL1833786 | 0.80 | ALDH1A1 (0.61) | TP53TSHRALDH1A1AOC3TAAR1 | |
| Ethylbenzene SCHEMBL11223212 | 0.80 | TP53 (1.00) | TP53TSHRALDH1A1TAAR1RAB9A | |
| Ethylbenzene SCHEMBL3987542 | 0.80 | TP53 (1.00) | TP53TSHRALDH1A1TAAR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409899-B2 | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | claimed |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | claimed |
| WO-2014178068-A2 | AN IMPROVED PROCESS FOR PREPARATION OF N-[1-(1-NAPHTHYL)ETHYL] -3- [3-(TRIFLUOROMETHYL)PHENYL]PROPAN-1-AMINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-11-06 | — | — | WO | claimed |
| US-20140179713-A1 | POLYMORPHIC FORM OF 5-(4-[4-(5-CYANO-1H-INDOL-3-YL) BUTYL] PIPERAZIN-1-YL) BENZOFURAN-2-CARBOXAMIDE AND PROCESS FOR PREPARING THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-06-26 | — | — | US | claimed |
| WO-2014072998-A1 | AN IMPROVED PROCESS FOR PREPARATION OF AGOMELATINE | CADILA HEALTHCARE LIMITED (IN) | 2014-05-15 | — | — | WO | claimed |
| WO-2014064715-A2 | AMORPHOUS FORM OF VILAZODONE HYDROCHLORIDE AND PROCESS FOR PREPARING THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-05-01 | — | — | WO | claimed |
| WO-2013175499-A2 | POLYMORPHIC FORM OF 5-(4-[4-(5-CYANO-1H-INDOL-3- YL)BUTYL]PIPERAZIN-1-YL) BENZOFURAN-2-CARBOXAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2013-11-28 | — | — | WO | claimed |
| WO-2013121440-A1 | PROCESS FOR PREPARING BENZISOTHIAZOL-3-YL-PEPERAZIN-L-YL-METHYL-CYCLO HEXYL-METHANISOINDOL-1,3-DIONE AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2013-08-22 | — | — | WO | claimed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| WO-2013072935-A2 | PROCESS FOR THE PREPARATION OF SILODOSIN | CADILA HEALTHCARE LIMITED (IN) | 2013-05-23 | — | — | WO | claimed |
| CN-103852983-B | Positively chargeable monolayer electrophotographic photosensitive member and image forming apparatus | 京瓷办公信息系统株式会社 | 2017-04-12 | — | — | CN | disclosed |
| CN-105980331-A | Dielectric material and electrostatic chucking device | 住友大阪水泥股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-102762519-B | Sintered body and manufacture method thereof | 住友大阪水泥股份有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9409899-B2 | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| WO-2014064715-A2 | AMORPHOUS FORM OF VILAZODONE HYDROCHLORIDE AND PROCESS FOR PREPARING THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013175499-A2 | POLYMORPHIC FORM OF 5-(4-[4-(5-CYANO-1H-INDOL-3- YL)BUTYL]PIPERAZIN-1-YL) BENZOFURAN-2-CARBOXAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013121440-A1 | PROCESS FOR PREPARING BENZISOTHIAZOL-3-YL-PEPERAZIN-L-YL-METHYL-CYCLO HEXYL-METHANISOINDOL-1,3-DIONE AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013072935-A2 | PROCESS FOR THE PREPARATION OF SILODOSIN | CADILA HEALTHCARE LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179713-A1 | POLYMORPHIC FORM OF 5-(4-[4-(5-CYANO-1H-INDOL-3-YL) BUTYL] PIPERAZIN-1-YL) BENZOFURAN-2-CARBOXAMIDE AND PROCESS FOR PREPARING THEREOF | CYP3A5, HTR3C, HTR5A | TP53 2078/4885TSHR 2126/4885ALDH1A1 480/4885 |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, F2 | TP53 1264/4885TSHR 2974/4885ALDH1A1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.